Protection from Psoriasis-Related Thrombosis after Inhibition of IL-23 or IL-17A

Psoriasis patients experience chronic systemic skin inflammation and develop cardiovascular comorbidities that shorten their lifespan. Whether cardiovascular disease is improved by treatment with current biologics that target disease-specific pathways is unclear. KC-Tie2 mice develop psoriasiform sk...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of investigative dermatology 2018-02, Vol.138 (2), p.310-315
Hauptverfasser:	Li, Yumeng, Golden, Jackelyn B., Camhi, Maya I., Zhang, Xiufen, Fritz, Yi, Diaconu, Doina, Ivanco, Tammy L., Simon, Daniel I., Kikly, Kristine, McCormick, Thomas S., Wang, Yunmei, Ward, Nicole L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Biological Products - pharmacology Biological Products - therapeutic use Carotid Arteries CD4-Positive T-Lymphocytes - drug effects CD4-Positive T-Lymphocytes - immunology Disease Models, Animal Female Humans Interleukin-17 - antagonists & inhibitors Interleukin-17 - immunology Interleukin-17 - metabolism Interleukin-23 - antagonists & inhibitors Interleukin-23 - immunology Interleukin-23 - metabolism Male Mice Mice, Transgenic Molecular Targeted Therapy - methods Monocytes - drug effects Monocytes - immunology Neutrophils - drug effects Neutrophils - immunology Psoriasis - complications Psoriasis - drug therapy Psoriasis - immunology Skin - drug effects Skin - immunology Skin - metabolism Spleen - cytology Spleen - drug effects Spleen - immunology Thrombosis - immunology Thrombosis - prevention & control Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!